首页> 外文期刊>Autoimmunity reviews >Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors
【24h】

Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors

机译:对118例无预后不良的结节性多发性动脉炎或镜下性多发性血管炎患者进行的随机试验的长期随访

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The purpose of this study was to assess the long-term outcomes of patients with polyarteritis nodosa (PAN) or microscopic polyangiitis (MPA) without Five-Factor Score (FFS)-defined poor-prognosis factors (FFS = 0) and enrolled in a prospective clinical trial. Patients were followed (2005-2012) under routine clinical care in an extended study and data were recorded prospectively. Long-term survival, disease-free survival (DFS), relapses, therapeutic responses and sequelae were analyzed. Mean ± SD follow-up was 98.2 ± 41.9. months. After having initially received glucocorticoids (GC) alone, according to the study protocol, 82% (97/118) patients achieved remission but 18% (21/118) required ≥ 1 immunosuppressant(s) (IS) before 19/21 achieved remission. Two patients died before entering remission. After remission, 53% (61/116) patients relapsed 25.6 ± 27.9. months after starting treatment. The 5- and 8-year overall survival rates were 93% and 86%, respectively, with no difference between PAN and MPA, and between relapsers and nonrelapsers. DFS was shorter for MPA than PAN patients (P = 0.02). Throughout follow-up, 47% of patients required ≥ 1 IS. At the last follow-up visit, 44% were still taking GC and 15% IS. The mean vasculitis damage index score was 1.9 ± 1.9; the most frequent sequelae were peripheral neuropathy, hypertension and osteoporosis. For PAN or MPA patients without poor-prognosis factors at diagnosis and treated initially with GC alone, long-term survival was excellent. However, relapses remained frequent, requiring IS introduction for nearly half of the patients. To lower the frequencies of relapses and sequelae remains a challenge for FFS = 0 PAN and MPA patients.
机译:这项研究的目的是评估结节性多动脉炎(PAN)或无五因素评分(FFS)定义的不良预后因素(FFS = 0)的微观多发性血管炎(MPA)患者的长期预后,并纳入前瞻性临床试验。在一项扩展研究中对患者进行常规临床护理(2005-2012年),并对其前瞻性记录数据。分析了长期生存,无病生存(DFS),复发,治疗反应和后遗症。平均±SD随访为98.2±41.9。个月。根据研究方案,最初仅接受糖皮质激素(GC)治疗后,有82%(97/118)的患者实现了缓解,但18%(21/118)的患者在19/21达到缓解之前需要≥1种免疫抑制剂(IS) 。两名患者在进入缓解之前死亡。缓解后,有53%(61/116)的患者复发了25.6±27.9。开始治疗后的几个月。 5年和8年总生存率分别为93%和86%,PAN和MPA以及复发者和非复发者之间无差异。 MPA的DFS比PAN患者短(P = 0.02)。在整个随访过程中,47%的患者需要≥1 IS。在上次随访中,仍有44%的人服用GC,15%的IS服用。平均血管炎损害指数评分为1.9±1.9;最常见的后遗症是周围神经病变,高血压和骨质疏松症。对于诊断时没有不良预后因素且最初仅用GC治疗的PAN或MPA患者,长期存活率是极好的。但是,复发仍然很频繁,需要将近一半的患者引入IS。对于FFS = 0 PAN和MPA患者,降低复发和后遗症的频率仍然是一个挑战。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号